Abstract
The most popular current hypothesis is that Alzheimers disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ- secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective druglike molecule targeting novel mechanisms of BACE-1 regulation.
Keywords: BACE-1, Secretase, Memapsin, Alzheimer, Amyloid, Aspartyl protease
CNS & Neurological Disorders - Drug Targets
Title: Beta-Secretase: Structure, Function, and Evolution
Volume: 7 Issue: 3
Author(s): Chitra Venugopal, Christina M. Demos, K. S. Jagannatha Rao, Miguel A. Pappolla and Kumar Sambamurti
Affiliation:
Keywords: BACE-1, Secretase, Memapsin, Alzheimer, Amyloid, Aspartyl protease
Abstract: The most popular current hypothesis is that Alzheimers disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ- secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective druglike molecule targeting novel mechanisms of BACE-1 regulation.
Export Options
About this article
Cite this article as:
Venugopal Chitra, Demos M. Christina, Jagannatha Rao S. K., Pappolla A. Miguel and Sambamurti Kumar, Beta-Secretase: Structure, Function, and Evolution, CNS & Neurological Disorders - Drug Targets 2008; 7 (3) . https://dx.doi.org/10.2174/187152708784936626
DOI https://dx.doi.org/10.2174/187152708784936626 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Editorial [Hot topic: Transgenic Animal Models of Neurodegenerative Diseases (Guest Editor: Stephen D. Skaper)]
CNS & Neurological Disorders - Drug Targets Conference Report (42nd Annual Meeting of the Italian Society of Neurology, 22-25 October 2011, Turin, Italy)
CNS & Neurological Disorders - Drug Targets Role of the Autonomic Nervous System and Neuropeptides in the Development of Obesity in Humans: Targets for Therapy?
Current Pharmaceutical Design Editorial: Applications of Medicinal Bioinorganic Chemistry
Current Medicinal Chemistry The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators
Mini-Reviews in Medicinal Chemistry Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Fluorescent Imaging Applications of Quantum Dot Probes
Current Nanoscience Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry Cellular and Pharmacological Targets to Induce Coronary Arteriogenesis
Current Cardiology Reviews Synthesis, Characterization and Antibacterial Evaluation of some New 1,2,4-triazolo[3,4-b][1,3,4]thiadiazines as Potential Antibacterial Agents
Letters in Drug Design & Discovery Crosstalk Between the Angiotensin and Endothelin-System in the Cerebrovasculature
Current Neurovascular Research Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Recent Applications of Birch Reduction in Total Synthesis of Natural Products
Current Organic Chemistry Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics RNA-Loaded Chitosan Nanoparticles for Enhanced Growth, Immunostimulation and Disease Resistance in Fish
Current Nanoscience